匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响

doi:10.3969/j.issn.1671-7171.2019.08.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】分析匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响。【方法】选择本院收治的136例慢性心衰患者,根据用药不同将其分为观察组(曲美他嗪+匹伐他汀,n=70)和对照组(曲美他嗪,n=66)。比较两组治疗前后心功能指标[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)以及左心室射血分数(LVEF)]、6min步行试验、血浆神经内分泌因子水平[血浆心钠素(ANP)、血浆脑钠肽(BNP)、血浆内皮素(ET)]。【结果】治疗后两组患者LVEDD、LVESD低于治疗前,LVEF高于治疗前,且组间比较差异均有统计学意义(均P<0.05)。治疗后观察组、对照组6 min步行距离均大于治疗前,且观察组大于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血浆ANP、BNP、ET水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。【结论】匹伐他汀联合曲美他嗪可有效抑制慢性心衰患者神经内分泌系统过度激活,逆转心室重塑,疗效较佳,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：心力衰竭/药物疗法, 曲美他嗪/药理学, 羟甲基戊二酰基CoA还原酶抑制剂/药理学

Abstract：【Objective】To analyze the effects of Pivastatin combined with Trimetazidine on neuroendocrine factors and cardiac function in patients with chronic heart failure. 【Methods】One hundred and thirty-six patients with chronic heart failure admitted to our hospital were divided into observation group (trimetazidine + pitavastatin, n=70) and control group (trimetazidine, n=66) according to different medications. The cardiac function indexes [left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)], 6-minute walking test, plasma levels of neuroendocrine factors [plasma atrial natriuretic peptide (ANP), plasma brain natriuretic peptide (BNP), plasma endothelin (ET)] were compared between the two groups before and after treatment. 【Results】After treatment, the LVEDD and LVESD of the two groups were lower than before treatment, and the LVEF was higher than before treatment, and the difference between the two groups was statistically significant (P<0.05). After treatment, the 6-minute walking distance of the observation group and the control group was greater than that before treatment, and the observation group was larger than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of plasma ANP, BNP and ET in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05).【Conclusion】Pivastatin combined with trimetazidine can effectively inhibit the overactivation of neuroendocrine system and reverse ventricular remodeling in patients with chronic heart failure. It has a good effect and is worthy of clinical application.

Key words： Heart Failure/DT Trimetazidine/PH Hydroxymethylglutaryl-CoA Reductase Inhibitors/PH

收稿日期: 2019-04-15

PACS:

R541.61

基金资助:韶关市卫生计生科研项目(编号Y18178)

引用本文:

谭德胜, 曹刚, 徐强, 梁心慧, 周凤, 沈颖, 林琳, 许宁. 匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响[J]. 医学临床研究, 2019, 36(8): 1531-1532.
TAN De-sheng, CAO Gang, XU Qiang,et al. Effect of Pivastatin Combined with Trimetazidine on Neuroendocrine Factor and Cardiac Function in Patients with Chronic Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2019, 36(8): 1531-1532.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.08.027 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I8/1531